Imagen de Portada

Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Mona Abdel‐Bary, Andrea Brody, Jenna Schmitt, Karen Prieto, Amy Wetzel, Yen‐Yi Juo
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Diabetes, Obesity and Metabolism
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
por: Jessica Van Laren, et al.
Publicado: (2026)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
por: Yunwen Xu, et al.
Publicado: (2025)

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
por: Yu‐Nan Huang, et al.
Publicado: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
por: Fu‐Shun Yen, et al.
Publicado: (2025)

Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
Publicado: (2025)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
por: David C. Klonoff, et al.
Publicado: (2024)

Effectiveness and care continuity in an app‐based, glucagon‐like peptide‐1 receptor agonist‐supported weight‐loss service for women with overweight and obesity in the UK : A real‐world retrospective cohort analysis
por: Louis Talay, et al.
Publicado: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
por: Darren Lau, et al.
Publicado: (2024)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
por: Karen L. Jones, et al.
Publicado: (2024)

Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
por: Chia‐Ming Lin, et al.
Publicado: (2025)

Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
por: Faisal I. Almohaileb, et al.
Publicado: (2025)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
por: Yi‐Chang Chou, et al.
Publicado: (2025)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
por: Stephanie L. Samuels, et al.
Publicado: (2024)

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
por: Neeta B. Amin, et al.
Publicado: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
por: Julio Rosenstock, et al.
Publicado: (2025)

Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice
por: Qilong Zhang, et al.
Publicado: (2025)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
por: Conner E. Johnson, et al.
Publicado: (2024)

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
por: Carel W. le Roux, et al.
Publicado: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
por: Filip K. Knop, et al.
Publicado: (2024)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
por: Jincheng Shen, et al.
Publicado: (2025)

Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
por: Donna Shu‐Han Lin, et al.
Publicado: (2024)

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial
por: Kelli M. Richardson, et al.
Publicado: (2025)

Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study
por: Raffaele Napoli, et al.
Publicado: (2024)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
por: Irl B. Hirsch, et al.
Publicado: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
por: Ruoyang Jiao, et al.
Publicado: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
por: Tae Hyeon Kim, et al.
Publicado: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
por: Juliana de Oliveira Costa, et al.
Publicado: (2024)

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies
por: Clare Buckeridge, et al.
Publicado: (2024)

Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice
por: Yuichiro Iwamoto, et al.
Publicado: (2024)

The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
por: Yu Zhang, et al.
Publicado: (2024)

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials
por: Dongjin Yeo, et al.
Publicado: (2025)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
por: Lucas Duchemin, et al.
Publicado: (2025)

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
por: Kevin Cowart, et al.
Publicado: (2025)

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes
por: Kathrine Kold Sørensen, et al.
Publicado: (2026)

Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
por: Luděk Horváth, et al.
Publicado: (2025)

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials
por: Gaspar R. Chiappa, et al.
Publicado: (2026)

Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
por: Muhammad Aaqib Shamim, et al.
Publicado: (2024)

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
por: Shunichiro Tsukamoto, et al.
Publicado: (2024)